Tirzepatide, a dual GIP/GLP-1 peptide
Tirzepatide, a single engineered peptide that activates both the GIP and GLP-1 receptors, produced large weight reduction in a phase 3 obesity trial.
What the study found
SURMOUNT-1 (New England Journal of Medicine, 2022) was a randomized phase 3 trial of once-weekly tirzepatide in adults with obesity. Tirzepatide is a single engineered peptide that activates both the GIP and GLP-1 receptors — two gut-hormone pathways involved in appetite and metabolism. Participants who received tirzepatide lost substantially more weight than those on placebo, alongside lifestyle measures. This describes what the trial measured; it is not advice, and nothing here recommends any medicine.
The peptide-engineering angle
Where earlier GLP-1 medicines mimic a single incretin hormone, tirzepatide is deliberately designed to hit two receptors with one molecule. Like other long-acting peptide drugs, it is chemically modified to resist the enzymes that would otherwise degrade a natural peptide within minutes, which is what allows once-weekly dosing. Because GIP and GLP-1 act through different tissues, engaging both may help explain a larger effect than targeting GLP-1 alone.
Analysis — the pattern
This extends a clear trend (analysis): after single-receptor GLP-1 peptides came multi-receptor "unimolecular" peptides, and triple-agonist peptides are now in trials. The signal is that combining several hormone pathways in one engineered peptide can amplify metabolic effects — an active, still-evolving research area rather than a settled endpoint.
What is still uncertain
Trials report averages, not individual outcomes. Gastrointestinal side effects are common, weight tends to return after the medicine is stopped, and long-term safety, effects on hard health outcomes beyond weight, and the best patient selection are all still being studied.